Live from #AACR26: Bruno Bockorny, MD (@BrunoBockorny @BIDMChealth) presents preliminary results of a phase 1, first-in-human, dose-escalation study of the anti-CCR8 antibody denikitug in participants with advanced solid tumors.

Key takeaways:

• Denikitug is pharmacologically active at doses ≥10 mg.
• As evidenced by changes in key biomarkers, including depletion of CCR8* itTregs and increases in activated Teffs.

• Antitumor activity was observed in heavily pretreated participants.
• Including those who were refractory to or had progressed on prior anti-PD-(L)1 therapy.

•Denikitug monotherapy demonstrated a manageable safety profile; observed TRAEs were consistent with an immunomodulatory MoA.

• The results support further evaluation of denikitug as monotherapy and as a potential combination partner with other treatments, such as anti-PD-(L)1 immunotherapies.

#MoffittAACR26